Niagen Bioscience (NAGE) Current Deferred Revenue (2016 - 2025)
Historic Current Deferred Revenue for Niagen Bioscience (NAGE) over the last 12 years, with Q3 2025 value amounting to $292000.0.
- Niagen Bioscience's Current Deferred Revenue rose 5869.57% to $292000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $292000.0, marking a year-over-year increase of 5869.57%. This contributed to the annual value of $611000.0 for FY2024, which is 21333.33% up from last year.
- Per Niagen Bioscience's latest filing, its Current Deferred Revenue stood at $292000.0 for Q3 2025, which was up 5869.57% from $303000.0 recorded in Q2 2025.
- In the past 5 years, Niagen Bioscience's Current Deferred Revenue registered a high of $611000.0 during Q4 2024, and its lowest value of $141000.0 during Q1 2022.
- Moreover, its 5-year median value for Current Deferred Revenue was $179500.0 (2021), whereas its average is $214055.6.
- Per our database at Business Quant, Niagen Bioscience's Current Deferred Revenue plummeted by 4208.63% in 2021 and then soared by 21333.33% in 2024.
- Quarter analysis of 5 years shows Niagen Bioscience's Current Deferred Revenue stood at $161000.0 in 2021, then fell by 2.48% to $157000.0 in 2022, then rose by 24.2% to $195000.0 in 2023, then surged by 213.33% to $611000.0 in 2024, then crashed by 52.21% to $292000.0 in 2025.
- Its last three reported values are $292000.0 in Q3 2025, $303000.0 for Q2 2025, and $207000.0 during Q1 2025.